Novo Nordisk, the maker of Ozempic, reported that compounded versions of semaglutide, the main ingredient in Ozempic and ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...

Wegovy® is the only version of semaglutide that is FDA-approved for weight loss, while Ozempic® and other forms of the drug ...

Novo Nordisk disclosed it knows of 10 deaths and 100 hospitalizations from people taking compounded copies of its weight loss ...

Both Ozempic and Wegovy are forms of semaglutide, a GLP-1 agonist drug manufactured by Novo Nordisk. When reached for comment ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Semaglutide (Wegovy) reduced pain and improved physical function in patients with obesity and knee osteoarthritis ...

The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versi ...

There are two ways to be eligible for a Wegovy prescription: Have a BMI of 30 or higher Have a BMI of 27 or higher and a ...

Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...

People who received weekly injections of semaglutide -- the active agent in the diabetes drug Ozempic and the weight-loss ...

Novo Nordisk has reported net Q3 profits of $3.94bn (DKr27.3bn) fuelled by better-than-expected sales for its blockbuster ...